Guides
Recovery & aftercare after cell therapy
Recovery and follow-up depend on the exact procedure, product, route and underlying condition. Use the treating team's written discharge plan and seek local clinical care for urgent or worsening symptoms.
Before discharge, ask the treating clinician to explain what was administered or performed, the immediate findings, expected short-term effects and the symptoms that require urgent assessment. There is no universal recovery schedule for interventions marketed as stem-cell therapy.
Obtain instructions that are specific to the procedure and your condition. They should cover wound or injection-site care, activity, medicines, driving, bathing, travel and any restrictions; generic online timetables cannot replace those instructions.
Agree an escalation plan before leaving the facility. New severe pain, breathing difficulty, weakness, confusion, high fever or rapidly worsening symptoms require prompt medical assessment; do not wait for a marketing coordinator or a routine video appointment.
Rehabilitation should be based on an assessment by an appropriately qualified professional. Physiotherapy may be part of standard care for some musculoskeletal or neurological conditions, but its timing, intensity and goals are not evidence that a cell product has integrated or worked.
Do not start, stop or avoid an anti-inflammatory medicine, antibiotic, anticoagulant or supplement because of a general claim about cell survival. Ask the prescriber to reconcile every medicine against the procedure, your conditions and your usual treatment.
Follow-up dates should reflect the protocol, product and clinical risk rather than a fixed commercial calendar. Record who will review you, which assessments are required, whether remote review is sufficient and who acts if a result is abnormal.
Imaging and laboratory tests should have a stated clinical or protocol purpose. A scan change alone may not show that symptoms or function improved, while symptom change alone may not establish that an investigational product caused it.
Define outcomes before treatment using measures relevant to the condition. Baseline and follow-up assessments reduce hindsight bias, but they do not turn an uncontrolled commercial intervention into evidence of efficacy.
Give your usual clinician the discharge summary, exact product or procedure name, dose and route, traceability details where applicable, medicines and adverse-event contact. Ask whether any established treatment needs to continue or restart.
Emotional distress after an uncertain intervention deserves ordinary clinical support. Contact an appropriate clinician or emergency service if anxiety, low mood or other symptoms become severe; the treating provider should not be the only source of support.
Long-term surveillance may be required by an authorised trial, marketing authorisation or national exemption. Ask how long safety data will be collected, what happens if the provider closes and how important new information will reach you.
Keep copies of consent, invoices, product and batch details, discharge records, test results and correspondence. The FDA adverse-event guide illustrates the product and provider details regulators need; use the reporting route for the country where care occurred.
Use the cost worksheet, then verify the exact product, evidence, legal route and written quotation with an independent qualified clinician.
Sources & further reading
- Stem-cell trials registry (ClinicalTrials.gov) ↗
- Peer-reviewed research (PubMed) ↗
- ISSCR — patient resources ↗
- FDA — consumer guidance ↗
- EMA — ATMP framework ↗
Educational guide; most uses are investigational. Verify the exact product, indication and provider with current regulator records and an independent qualified physician.